• TruePrime™ Single Cell WGA kit to be launched early 2015
• European distribution agreement with focus on main markets
• Sales expected to start directly with product launch
Madrid, Spain and Heidelberg, Germany, December 8, 2014 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it has signed an initial distribution agreement for its first proprietary product with German BioCat GmbH.
With this agreement, SYGNIS grants BioCat non-exclusive rights to promote, market, sell, and support TruePrime™ Single Cell WGA kit for the DNA amplification of single cells for next generation sequencing (NGS) applications. TruePrime™ Single Cell WGA kit will be the first in a row of products of SYGNIS’ TruePrime™ product family for the amplification of various DNA or RNA species for a multitude of applications and is expected to be launched in January 2015.
As a highly specialized solution provider, BioCat is offering a wide range of high-quality research reagents as well as cutting-edge technologies in the fields of genomics, proteomics, and cell biology to customers all over Europe.
“We are very pleased about this distribution agreement for our first proprietary product with a strong and important partner like BioCat. With its wide customer network focused on molecular biology and its unparalleled logistics, BioCat provides the ability to leverage the benefits of this new technology to researchers working in the fast growing field of NGS,” Pilar de la Huerta, CEO and CFO of SYGNIS commented. “Having TruePrime™ Single Cell WGA kit now widely available in Europe, is a major achievement in our new product and commercialization strategy. In addition, signing such a contract prior to product launch, proves the attractiveness of TruePrime™ Single Cell WGA kit and shows the faith and confidence of market expert BioCat in our product.”
“We’re excited about adding SYGNIS’ products to our portfolio of innovative products and technologies for researchers working in the molecular biology field”, Dr. Michael Ehret, CEO of BioCat GmbH added. “The superior features of TruePrime™ make it highly attractive for use in areas such as human genetics, oncology, or pathology where researchers need to obtain biological information from the smallest amounts of samples. This agreement will provide us with a product to more effectively address the fast growing market of next generation sequencing.”
About TruePrime ™
TruePrime™ Single Cell WGA kit uses a revolutionary novel multiple displacement amplification method based on the combination of the recently discovered polymerase “TthPrimPol” and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA either from a single or a few cells. The extraordinary strand displacement capacity of the Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification.
About the Next Generation Sequencing market
Today, NGS is seen as the fastest-growing and most lucrative segment in the genomics market with an estimated annual growth rate of more than 23% in the years to come. The global NGS market volume today is worth $2.5 billion and is poised to reach $8.7 billion by 2020 (MarketsandMarkets, September 2014). While still mostly used in research institutions, ongoing developments for higher throughput, increased accuracy, and cost efficiency as well as value creating data management will make NGS more and more attractive for commercial applications such as diagnostics, drug discovery, biomarker discovery as well as personalized medicine in clinical laboratories, hospitals and in pharmaceutical companies.
For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.es
Help employers find you! Check out all the jobs and post your resume.
